Researchers found that the SARS-CoV-2 receptor, ACE2 and related entry factors were expressed in β-cells, with selectively high expression of NRP1.
7753456 RQPUA6P3 items 1 apa default asc 1
Wu, C.-T., Lidsky, P. V., Xiao, Y., Lee, I. T., Cheng, R., Nakayama, T., Jiang, S., Demeter, J., Bevacqua, R. J., Chang, C. A., Whitener, R. L., Stalder, A. K., Zhu, B., Chen, H., Goltsev, Y., Tzankov, A., Nayak, J. V., Nolan, G. P., Matter, M. S., … Jackson, P. K. (2021). SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment. Cell Metabolism, 0(0). https://doi.org/10.1016/j.cmet.2021.05.013 Cite
Researchers showed that leptin receptor (LepR)-expressing neurons in arcuate (LepRArc) are selectively activated in type-1 diabetes.
7753456 ZAV9HR3C items 1 apa default asc 1
Fan, S., Xu, Y., Lu, Y., Jiang, Z., Li, H., Morrill, J. C., Cai, J., Wu, Q., Xu, Y., Xue, M., Arenkiel, B. R., Huang, C., & Tong, Q. (2021). A neural basis for brain leptin action on reducing type 1 diabetic hyperglycemia. Nature Communications, 12(1), 2662. https://doi.org/10.1038/s41467-021-22940-4 Cite
Investigators showed that inhibiting serpinB13, a cathepsin L protease inhibitor expressed in the pancreatic epithelium, caused in vitro and in vivo cleavage of the extracellular domain of Notch1.
[Science Translational Medicine]
Researchers developed a lotus-root-shaped cell-encapsulated construct as a graft that can be retrieved after long-term human-stem-cell-derived pancreatic beta cell transplantation.
6445218 Y5UFWJU5 items 1 apa default asc 1
Researchers suggested that accumulation of endogenous mtdsRNA following degradosome knockdown depended on the proliferative capacity of the cells and was not a mediator of the type I interferon response in human pancreatic beta cells.
6606345 U4LAC9M3 items 1 apa default asc 1
Coomans de Brachène, A., Castela, A., Musuaya, A. E., Marselli, L., Marchetti, P., & Eizirik, D. L. (2021). Endogenous mitochondrial double‐stranded RNA is not an activator of the type I interferon response in human pancreatic beta cells. Autoimmunity Highlights, 12(1), 6. https://doi.org/10.1186/s13317-021-00148-2 Cite
While much has been learned about type 1 diabetes (T1D), it is now clear that there is considerable heterogeneity in T1D with regards to genetics, pathology, response to immune-based therapies, clinical course, and susceptibility to diabetes-related complications. This review highlights knowledge gaps and opportunities to improve the understanding of T1D pathogenesis and outlines emerging therapies to treat or prevent T1D and reduce the burden of T1D.
[Journal of Clinical Investigation]
To investigate islet sympathetic innervation in type 1 diabetes (T1D), sympathetic tyrosine hydroxylase axons were analyzed in control non-diabetic organ donors, non-diabetic islet autoantibody-positive individuals, and age-matched persons with T1D.
6807162 4A4LBB4I items 1 apa default asc 1
Campbell-Thompson, M., Butterworth, E. A., Boatwright, J. L., Nair, M. A., Nasif, L. H., Nasif, K., Revell, A. Y., Riva, A., Mathews, C. E., Gerling, I. C., Schatz, D. A., & Atkinson, M. A. (2021). Islet sympathetic innervation and islet neuropathology in patients with type 1 diabetes. Scientific Reports, 11(1), 6562. https://doi.org/10.1038/s41598-021-85659-8 Cite
The authors assessed the therapeutic potential of co-administration of human clonal mesenchymal stem cells and liraglutide as a glucagon-like peptide-1 agonist in a non-human primate model with streptozotocin-induced diabetes.
1254621 ITSNEW4H items 1 apa default asc 1
Navabi, R., Negahdari, B., Hajizadeh-Saffar, E., Hajinasrollah, M., Jenab, Y., Rabbani, S., Pakzad, M., Hassani, S.-N., Hezavehei, M., Jafari-Atrabi, M., Tahamtani, Y., & Baharvand, H. (2021). Combined therapy of mesenchymal stem cells with a GLP-1 receptor agonist, liraglutide, on an inflammatory-mediated diabetic non-human primate model. Life Sciences, 119374. https://doi.org/10.1016/j.lfs.2021.119374 Cite
Evolve BioSystems, Inc. announced that its product, activated B. infantis EVC001, will be used in one of the largest international clinical studies on preventing type 1 diabetes in genetically predisposed children. The randomized, controlled, double-blind, multicenter trial will be conducted across eight major research centers in five European countries.
[Evolve BioSystems, Inc.]
6807162 nan items 1 apa default asc 1
ViaCyte, Inc. and W. L. Gore & Associates, Inc. announced the two companies have signed an expanded joint development agreement covering the development and use of proprietary Gore materials and device capabilities to further optimize ViaCyte’s portfolio of product candidates for the treatment of diabetes.
[ViaCyte, Inc. (PR Newswire, Inc.)]
6606345 nan items 1 apa default asc 1
JDRF announced, in collaboration with the Harvard Stem Cell Institute, the launch of the JDRF Center of Excellence in New England.
[JDRF (PR Newswire, LLC)]
6807162 nan items 1 apa default asc 1